Certara Reports Third Quarter 2022 Financial Results

Biosimulation software and services fuel third quarter growth PRINCETON, N.J.— November 7, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance. Third Quarter Highlights: Revenue was $84.7 million, compared to $73.9 million in the third … Continued

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares PRINCETON, N.J.— November 7, 2022 — Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare … Continued

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J.— November 2, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Jeffries London Healthcare ConferenceDate and Time: Tuesday, November 15 at 4:25PM GMT Stephens Annual Investment ConferenceDate and Time: Thursday, November 17 at 9:00AM CT Live webcasts for each … Continued

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions

The PMDA enters 9th consecutive year of using Certara’s software PRINCETON, N.J., October 19, 2022 — Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ Simulator, Phoenix™ biosimulation software, and Pinnacle 21™ Enterprise software.  “The adoption of biosimulation … Continued

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J.— August 31, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Morgan Stanley 20th Annual Global Healthcare ConferenceDate and Time: Tuesday, September 13 at 11:45 a.m. ET Baird Global Healthcare ConferenceDate and Time: Wednesday, September 14 at 12:15 p.m. … Continued

Certara Reports Second Quarter 2022 Financial Results

Biosimulation software and services fuel second quarter growth PRINCETON, N.J.—August 9, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights: Revenue was $82.8 million, compared to $70.1 million in the second quarter … Continued

Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J., August 5 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s flagship software for validating clinical trial data for biosimulation and regulatory submissions.  It also introduced the new … Continued

Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies

Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies PRINCETON, N.J.— July 28, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop new biosimulation software. Certara will be working with the MSK Innovation … Continued

Certara Appoints Rosemary Crane as New Independent Board Member

PRINCETON, N.J., July 25, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022.  Her appointment brings the company’s board of directors to eleven members. “We are excited to welcome an accomplished business leader with a proven track … Continued

1 of 30
Powered by Translations.com GlobalLink OneLink Software